AndreasVarkaris

Just ran a poll asking you to label iron indices, and 60% of you got it right! 👏 Bottom line in iron deficiency: ⬆️ Fe absorption (low hepcidin → gut) ⬆️ Transferrin (liver) → ⬆️ TIBC ⬇️ TSAT ⬇️ Ferritin (macrophages) Nice work, #MedTwitter! #HemePearls #IronMetabolism

Excellent review: INAVO120 marks a turning point, despite limitations. Previous treatment boundaries are breaking. Triplet combinations — hormonal therapy, CDK4/6 inh and PI3K inh— are now clinically achievable. Early genomic testing matters. ascopubs.org/doi/full/10.12…

Diagnosis of iron deficiency in patients with cancer requires different thresholds. Excellent review from the BIDMC hematology team. Evaluation and Treatment of Iron Deficiency for the Practicing Oncologist | JCO Oncology Practice ascopubs.org/doi/abs/10.120…

CXCR4 partial agonism TFF2-MSA restores anti-PD-1 sensitivity by targeting immunosuppressive neutrophils and granulopoiesis.

Thrilled to share this exciting study ⁦@NatureMedicine⁩. Largest integrative analysis of #sotorasib efficacy biomarkers to date. Grateful to all co- investigators and the Amgen team for their hard work and most of all to our patients. ⁦@MDAndersonNews⁩ #KRAS #NSCLC

Clinical trials drive progress in cancer treatment, yet only 3% of cancer patients in the U.S. participate. Misinformation plays a big role. Swipe through to learn the truth about clinical trials and why they matter for advancing cancer care. Learn more: bit.ly/4df9RMB

It was great to see some of our investigators presenting their research at #AACR25! Check out these posters from Ferran Fece de la Cruz, PhD, from @MassGeneralNews and Andrea Romanos-Nanclares, PhD, from @BrighamWomens.

Lots of #KRAS at #AACR25! Incredible to think that Ras was “undruggable” <10yrs ago and now >50 clinical trials! Next, how to tackle resistance? @andrewaguirremd explains diverse resistance mutations and potential combos

Exciting news! Congratulations to Dr Nicholas Turner, all study staff and investigators, and most importantly to our patients and their families. #BreastCancerAwarenessMonth #bcsm @OncoAlert @MSKCancerCenter

.@skopetz lays out the pathway to regulatory approval and clinical incorporation of MRD (of which the very definition is fluid! Minimal? Molecular? Measurable?) into patient management, especially in solid tumors Not all tests are created equal #ASCO24

⁦@KalinskyKevin⁩ presents postMONARCH, the first trial showing benefit of continuing CDK4/6 inhibition after progression on prior CDK. Congrats to investigators, including senior author ⁦@MGHCancerCenter⁩ ⁦@MGHBreastOnc⁩ Seth Wander #ASCO24

Amazing to celebrate the brilliant Conquer Cancer Foundation grant awardees, especially proud of ⁦⁦@RachelAbelman⁩ Ellis, Leon Pappas YIA winners and Catherine Meador CDA winner of ⁦@MGHCancerCenter⁩ #ASCO24

BIDMC Postdoc and @AACR Grant Recipient @HogstromJenny presented her team's research findings yesterday, titled, "Mechanisms of Succinate-Mediated Drug Resistance in ER+ #BreastCancer". Congratulations on your great talk yesterday at #AACR24, Dr. Hogstrom!

The KRASG12C inhibitor adagrasib, paired with the EGFR inhibitor cetuximab, benefited patients with metastatic colorectal cancer in the KRYSTAL-1 trial, presented by Scott Kopetz, MD, PhD and published in @CD_AACR. bit.ly/4cQaZG4 #AACR24 @skopetz @MDAndersonNews

We congratulate the recipient of the AACR-Waun Ki Hong Award for Outstanding Achievement in Translational and Clinical Cancer Research, Scott Kopetz, MD, PhD. Dr. Kopetz will present his Award Lecture at #AACR24 on Sunday April 7, 4:30-5:15 PM. Learn more: bit.ly/3TEwaSz

Don’t miss this virtual info session! All interested attendees are welcome. Program highlights: ·         Single NRMP match ·         Consolidated training ·         Integrated curriculum @ASCO @ASCOTECAG @OncMedEdCoP

Sotorasib is a Pan-RASG12C-, with activity in NRASG12C+ cancers ⁦@CD_AACR⁩: - sotorasib 5x ⬆️potent against NRASG12C vs KRASG12C or HRASG12C (activity in all) - pt w NRASG12C+ CRC had prolonged response to soto+panitumumab ⁦@OncoAlert⁩ #LCSM aacrjournals.org/cancerdiscover…

Allosteric PIK3CA inhibitors hit the target sufficiently to cause responses without on-target toxicity!!!